Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: In patients at risk of hepatocellular carcinoma (HCC), new focal liver lesions identified at ultrasound screening require further characterization by CT or MRI. If these techniques cannot conclusively characterize a lesion, a biopsy or an alternative imaging modality such as contrast-enhanced ultrasound (CEUS) is considered. We aimed to determine the diagnostic yield of CEUS in a sequential noninvasive diagnostic strategy for solitary nodules ≤ 20 mm detected in cirrhotic patients during US surveillance characterized as inconclusive on MRI.
Methods: Post hoc analysis of a single-center prospective cohort of high-risk patients (Child A or B) with no prior history of HCC and new liver nodules (≤ 20 mm) detected on screening US who underwent CEUS after inconclusive MRI (LI-RADS-2, LI-RADS-3, LI-RADS-4, or LI-RADS-M) between January 2006 and February 2017. We compared the characterization of nodules by LI-RADS v.2018 alone vs characterization after considering subsequent CEUS-LR v.2017 against the final diagnosis by biopsy or follow-up.
Results: Of the 75 nodules included, CEUS upgraded 45 (63.4%); of these, 13 nodules classified as LR3 or LR4 at MRI were classified as CEUS-LR5. Altogether, 15 (21.1%) nodules inconclusive on MRI were classified as CEUS-LR5. CEUS yielded 37.5% (95% CI: 22.73‒54.20%) sensitivity and 100% specificity (95% CI: 88.78-100%) for HCC.
Conclusion: Adding CEUS to the workup of liver nodules with inconclusive MRI findings demonstrated high specificity for HCC, particularly benefiting nodules categorized as LR3 at MRI.
Key Points: Question MRI's limited sensitivity in diagnosing small HCCs in cirrhotic patients results in inconclusive classification of a high proportion of screening-detected lesions. Findings Adding CEUS to the work-up for inconclusive liver nodules at MRI yielded 100% specificity (95% CI: 88.78-100%) and 37.5% (95% CI: 22.73-54.20%) sensitivity for the HCC diagnosis. Clinical relevance CEUS is a valuable problem-solving tool in the work-up of small liver nodules with inconclusive MRI findings in cirrhotic patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-025-11495-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low prevalence of hemoperitoneum recurrence in dogs following splenectomy for benign splenic tumors.
Front Vet Sci
August 2025
Ethos Discovery, Sorrento Valley, CA, United States.
Introduction: The purpose of this study is to describe the outcomes and prevalence of hemoperitoneum recurrence in dogs presumptively cured following splenectomy for spontaneously ruptured benign splenic lesions.
Methods: A retrospective analysis of a cohort of 83 client-owned dogs with spontaneous hemoperitoneum due to a histologically benign, bleeding splenic lesion was performed. Medical records of dogs with ruptured benign splenic tumors presenting with hemoperitoneum were reviewed, in addition to owner follow-up, to determine if subsequent hemoperitoneum events occurred.
Background: Since 2013, we have performed conversion surgery after hepatic arterial infusion chemotherapy (HAIC) for initially unresectable locally advanced hepatocellular carcinoma (LA-HCC).
Methods: Between 2013 and 2021, we assessed the surgical and oncological outcomes and pathological findings of patients with LA-HCC without extrahepatic spread (EHS) whose tumors converted from unresectable to resectable status with the New-FP regimen HAIC.
Results: We censored 153 patients with LA-HCC (Child-Pugh A, without EHS) indicated for HAIC.
Patent ductus venosus is a congenital portosystemic shunt that may cause progressive portal hypertension, hepatic encephalopathy, and focal nodular hyperplasia of the liver. Embolization of the Arantius' duct is the first choice of treatment in infants and children. However, it carries the risk of coil migration into the systemic circulation in adult patients with larger Arantius ducts.
View Article and Find Full Text PDFHepatic reactive lymphoid hyperplasia diagnosed through post-ablation liver tumor biopsy.
Clin J Gastroenterol
September 2025
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Hepatic reactive lymphoid hyperplasia (RLH), also known as hepatic pseudolymphoma, is a rare benign condition that predominantly affects middle-aged-to-elderly women and is often associated with autoimmune disorders. The imaging features of hepatic RLH frequently mimic those of malignant hepatic tumors, such as hepatocellular carcinoma (HCC), cholangiocarcinoma, or metastatic liver tumors, making its diagnosis based solely on imaging modalities challenging, often leading to unnecessary surgical resection. However, the optimal diagnostic strategy for hepatic RLH remains controversial.
View Article and Find Full Text PDFCombination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study.
J Cancer Res Ther
September 2025
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Objective: This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and without KRAS mutations.
Materials And Methods: We retrospectively collected data from patients with UCRLM, who received HAIC with HAICP or HAIC alone (oxaliplatin plus fluorouracil), including information on KRAS status (mutated, MUT; wild-type, WT) from a multicenter institutional database. Propensity score matching (PSM) was performed.